Phase II/III placebo-controlled trials evaluating deutetrabenazine for the treatment of tics in paediatric patients with Tourette Syndrome fail to meet primary endpoints

In ARTISTS 1 (Phase II/III; n=119) and ARTISTS 2 (Phase III; n=158) in children (6-16 yrs) with moderate to severe Tourette Syndrome, deutetrabenazine was not associated with a reduction in motor and phonic tics (assessed by Total Tic Score of the Yale Global Tic Severity Scale)

SPS commentary:

Deutetrabenazine is a deuterated form of tetrabenazine with pharmacokinetic properties that allow for more consistent blood levels and less frequent dosing. It is not currently available in the EU.


Biospace Inc.